Martien van Osch, Chairman

Martien is a founding partner at Forbion Capital Partners. He splits his time between investment related activities and the finance function. In terms of investment focus, Martien spearheads the medical device related activities at Forbion. He was responsible for the recent exit of Santaris Pharma AS to Roche in August 2014 for up to USD 450 million, the sale of Circulite, Inc. to Heartware, Inc. in December 2013 for up to USD 350 million and of Pathway Medical Technologies, Inc., sold to Bayer Medrad in 2011 for USD 125 million. He currently contributes to the boards of Mitralign, Inc. and PneumRx, Inc. His experience in the life sciences industry also includes prior non-executive board positions at Cambridge Drug Discovery Ltd., Impella Cardiosystems, Acadia Pharmaceuticals and Flowmedica, Inc. Martien holds a degree in Econometrics from the University of Groningen, the Netherlands.

Edward van Wezel, Board Member

Edward is founder of BioGeneration Ventures and has extensive international expertise in pharma and biotech companies. Edward started his industrial career as a process engineer for Chiron Inc. He was a project manager at Johnson & Johnson responsible for product development projects in the oncology franchise and was involved in corporate licensing activities. Since 2000 he gained experience as CEO of several early startup companies in the Netherlands. Edward holds a MSc in chemistry from the University of Utrecht and a MSc in biochemical engineering from the Delft University of Technology.

Hilde Steineger, CEO

Hilde H. Steineger joined Staten Biotech in December 2017. Prior to joining Staten Biotech, Hilde served as Head of Strategic Innovation Management in Nutrition and Health Division (EN), BASF and Head of Global Omega-3 innovation Management including; R&D, Medical affairs and Business Development. She has also served as Vice President, Head of Investor Relations for Pronova BioPharma, Senior Associate at Neomed Management and as a Senior sell-side Analyst at Nordea Securities.  She has for the last 15 years served as member of board of directors in a number of listed biotech companies, in Norway and in US. Dr. Hilde Steineger has broad scientific knowledge with a PhD in medical biochemistry from the University of Oslo in 2000 and an MSc in molecular biology/biotechnology from 1992.

Paul da Silva Jardine, Co-founder and CSO

Paul Da Silva Jardine is co-founder and CSO at Staten. He brings extensive know-how in drug development in the cardiovascular field. He is a former VP at Pfizer R & D who spent more than 24 years at Pfizer managing project teams delivering over 50 clinical candidates in cardiovascular, obesity, diabetes, and osteoporosis. He discovered Lasofoxifene and led early clinical development team to an approved compound in Europe. Most recently, he was VP for Research in the Cardiovascular and Metabolic Diseases (CVMED) Research Unit at Pfizer responsible for projects from target identification in the end of Phase 2.

Vincent van Houten, CFO

As of January 2017, Vincent is acting Chief Financial Officer for Staten.  Vincent holds a Master's degree from the University of Amsterdam, has a Finance and Accounting background, and has experience in corporate and fiscal (re)structuring. Vincent is primarily the Chief Financial Officer for Forbion and in that capacity, he is responsible for the overall financial and fiscal affairs of Forbion and its affiliates. As part of the Forbion Investment Team Vincent also has portfolio related financial topics and as such Vincent is seconded to Staten as acting CFO. Previously he has had a similar assignment for Forbion as acting Chief Financial Officer for Dezima Pharma BV, and played and active role in the acquisition of Dezima by Amgen in 2015.